All GLG News Analyses Filed Under: Endocrinology

The article published in the Lancet (Nov,2007), and reported in the www.pharmalive is highlighting the side-effects of Weight-Loss Drug Rimonabant, despite its potent beneficial effects to treat obesity. The report is a summary of a meta-analysis of four double-blind randomised controlled trials with 4105...

We have been hoping that remonibant, the cannabinoid antagonist, would allow patients with obesity to lose weight "pharmacologically" without actually having to undergo the significant effort to reverse a lifetime of self-destructive behaviors that have culminated in pathological obesity--obesity that...

As past Principal Investigator in most clinical trials wit Orlistat I can offer a different interpretations of tthe resuls of the comparayive study just announced,as follows.1.The result on diabetes or glucose regulation were earlier with Liraglutide,possibly because it has specific antidiabetic(besides...

This study demonstrated superiority of Forteo compared to Fosamax, and it offers a new useful altenative for rheumatologist to prevent complications of corticosterioid-induced osteoporosis. I believe that this new indication will expand the use of the dug in the most vulnerable population,...

The pooled analysis of Rimonabant trials point to a significant increase in psychiatric disorders. These studies also point to significant improvements in markers of cardiovascular risk. Risks versus benefits must be considered before the final decision is made on this class of medications.

Forteo is a very strong osteoporosis medication that is one of the only medications available that actually stimulates bone growth.  There are two types of cells in the bone (which is actually a living organ that remodels constantly over time) - Osteoblasts (bone builders) and Osteoclasts (bone...

The meta-analysis of the rimonabant trials points to an increase in psychiatric diagnoses. What is missing in this report is the numberical and statistical significance of the findings.  This debate needs more rigor; the type of rigor that is applied to cardiac endpoints, needs to be applied here. ...

Most diabetics have subclinical CAD, and a baseline risk of CAD equivalent to that of a person without diabetes and a prior MI.  This drug, by limiting its labelling is severely limiting its use in patients with diabetes.

GLG formally acknowledges FDA warnings on their TZD and further compromises physician use of product.

GlaxoSmithKline is taking a pragmatic step to safeguard diabetic patient's risk of having myocardial ischemia from the intake of Avandia, the oral antidiabetic medicine. The revised label will state that the available data on the risk of myocardial ischemia are inconclusive...